Difference between revisions of "Part:BBa K4156119"
Line 17: | Line 17: | ||
Characterization details can be found at: | Characterization details can be found at: | ||
− | pCadC-TP901:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part: | + | pCadC-TP901:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156099"> BBa_K4156099 </a></html> |
− | pCadC-TP901-φ174E:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part: | + | pCadC-TP901-φ174E:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156100"> BBa_K4156100 </a></html> |
− | pLldR-TP901:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part: | + | pLldR-TP901:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156104"> BBa_K4156104 </a></html> |
− | pLldR-TP901-φ174E:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part: | + | pLldR-TP901-φ174E:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156105"> BBa_K4156105 </a></html> |
− | pPepT-TP901:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part: | + | pPepT-TP901:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156108"> BBa_K4156108 </a></html> |
− | pPepT-TP901-φ174E:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part: | + | pPepT-TP901-φ174E:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156109"> BBa_K4156109 </a></html> |
Latest revision as of 01:59, 12 October 2022
XOR gate-HlyE
XOR gate-HlyE consists of an XOR logic gate ( BBa_K4156117 ) and a downstream HlyE ( BBa_K4156084 ) sequence, and tests the performance of the XOR gate by detecting the red fluorescent signal.
Usage and Biology
The construction of this part is similar to XOR gate-mRFP ( BBa_K4156124 ). The difference is that we replaced the mRFP protein with the HlyE therapeutic protein. This is to verify the therapeutic power of the recombinant strain under XOR gate control. After co-incubation of the recombinant strain with cancer cells, cell viability was monitored using the CCK8 assay to assess the therapeutic power of the recombinant strain and the reinforcing effect of the XOR gate.
Characterization
We used three different promoters in combination with XOR gate-HlyE to characterize the therapeutic efficacy of bacteria under the control of different promoters and TP901 coupled logic gates, and with the addition of lysis genes.
Characterization details can be found at:
pCadC-TP901: BBa_K4156099
pCadC-TP901-φ174E: BBa_K4156100
pLldR-TP901: BBa_K4156104
pLldR-TP901-φ174E: BBa_K4156105
pPepT-TP901: BBa_K4156108
pPepT-TP901-φ174E: BBa_K4156109
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 614
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 104
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 124
Illegal BsaI.rc site found at 351